Vaccination and immunization against travel-related diseases in immunocompromised hosts.

Abstract:

:Immunocompromised hosts are growing in number and include transplant recipients of solid organs or hematopoietic stem cells, people who have HIV, cancer patients on chemotherapy, patients on immunomodulatory treatments for rheumatologic, gastrointestinal or other conditions, as well as those with other immunocompromising conditions. As their overall health improves, they are more likely to initiate foreign travel and have potential exposures to endemic pathogens. Immunocompromised hosts are, in general, less likely to respond to vaccines and may be more likely to have side effects from certain vaccines, such as those containing live-attenuated virus. In addition, vaccines are immunomodulatory and could theoretically impact upon immunologic conditions. This review will summarize the medical literature regarding travel-related vaccines in the adult, immunocompromised-host population. Since the research in this realm is limited and exists primarily in the setting of solid-organ and hematopoietic stem cell transplant recipients and HIV-positive subjects, this review will largely focus on these populations.

journal_name

Expert Rev Vaccines

authors

Kotton CN

doi

10.1586/14760584.7.5.663

subject

Has Abstract

pub_date

2008-07-01 00:00:00

pages

663-72

issue

5

eissn

1476-0584

issn

1744-8395

journal_volume

7

pub_type

杂志文章,评审
  • Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.

    abstract:INTRODUCTION:Neisseria meningitidis causes invasive meningococcal disease (IMD), with the highest incidence observed in infants and young children. Meningococcal serogroups A, B, C, W, X, and Y account for almost all IMD cases worldwide. Available meningococcal vaccines targeting serogroups A, C, W, and Y (MenACWY) inc...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1745070

    authors: Martinón-Torres F,Serra L,Safadi MAP

    更新日期:2020-04-01 00:00:00

  • Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

    abstract::Recombinant modified vaccinia virus Ankara (MVA) is attractive and promising as a novel viral vector for the expression of foreign genes of interest because it possesses unique properties. In particular, its excellent safety profile and the availability of versatile vector technologies have frequently made MVA the vac...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.4

    authors: Rimmelzwaan GF,Sutter G

    更新日期:2009-04-01 00:00:00

  • International Dengue Vaccine Communication and Advocacy: Challenges and Way Forward.

    abstract::Dengue vaccine introduction will likely occur soon. However, little has been published on international dengue vaccine communication and advocacy. More effort at the international level is required to review, unify and strategically disseminate dengue vaccine knowledge to endemic countries' decision makers and potenti...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1152187

    authors: Carvalho A,Van Roy R,Andrus J

    更新日期:2016-01-01 00:00:00

  • Alternative administration routes and delivery technologies for polio vaccines.

    abstract::Global polio eradication is closer than ever. Replacement of the live attenuated oral poliovirus vaccine (OPV) by inactivated poliovirus vaccine (IPV) is recommended to achieve complete eradication. Limited global production capacity and relatively high IPV costs compared to OPV spur the need for improved polio vaccin...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1158650

    authors: Kraan H,van der Stel W,Kersten G,Amorij JP

    更新日期:2016-08-01 00:00:00

  • The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms.

    abstract::Introduction: For over 40 years, ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates across western and central Africa. In December 2013, an unprecedented Ebola virus (EBOV) epidemic began in West Africa and resulted in the largest outbr...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2020.1738225

    authors: O'Donnell K,Marzi A

    更新日期:2020-03-01 00:00:00

  • Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.

    abstract::As the Global Polio Eradication Initiative progresses toward the eradication of wild polioviruses, national and global health leaders must still actively consider options for managing poliovirus risks, including risks associated with using oral poliovirus vaccine. Oral poliovirus vaccine continues to represent a highl...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.195

    authors: Thompson KM,Tebbens RJ

    更新日期:2012-04-01 00:00:00

  • ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines.

    abstract::This review describes several enzyme-linked immunosorbent assay (ELISA) techniques proposed to replace the neutralization test for detecting neutralization-relevant antibodies to polioviruses in recipients of inactivated poliovirus vaccine and oral poliovirus vaccine, and for seroepidemiologic studies. Comparisons of ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.2.167

    authors: Ivanov AP,Dragunsky EM

    更新日期:2005-04-01 00:00:00

  • Development of Group A streptococcal vaccines: an unmet global health need.

    abstract::Group A Streptococcus (GAS) infections are a significant global cause of morbidity and mortality. GAS diseases disproportionally affect those living in conditions characterized by poverty and social injustice, in both developing countries and in marginalized populations of industrialized nations. In Australia and New ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1116946

    authors: Sheel M,Moreland NJ,Fraser JD,Carapetis J

    更新日期:2016-01-01 00:00:00

  • Current vaccine updates for lung cancer.

    abstract::Current treatments for lung cancer are far from optimal. Several immunotherapeutic strategies involving vaccines incorporating different tumor-associated antigens to induce immune responses against tumors are being tested in clinical trials internationally. Although small, benefits have indeed been observed from the e...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.12

    authors: Simmons O,Magee M,Nemunaitis J

    更新日期:2010-03-01 00:00:00

  • The potential of plants for the production and delivery of human papillomavirus vaccines.

    abstract::The available vaccines against human papillomavirus have some limitations such as low coverage due to their high cost, reduced immune coverage and the lack of therapeutic effects. Recombinant vaccines produced in plants (genetically engineered using stable or transient expression systems) offer the possibility to obta...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1037744

    authors: Rosales-Mendoza S,Govea-Alonso DO

    更新日期:2015-07-01 00:00:00

  • Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.

    abstract::Lipopolysaccharide (LPS), a dominant component of the Gram-negative bacterial outer membrane, is a strong activator of the innate immune system, and thereby an important determinant in the adaptive immune response following bacterial infection. This adjuvant activity can be harnessed following immunization with bacter...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1026808

    authors: Zariri A,van der Ley P

    更新日期:2015-06-01 00:00:00

  • Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?

    abstract::Neisseria lactamica is a commensal organism that is closely related to Neisseria meningitidis, the causative agent of meningococcal disease. N. lactamica has many antigens in common with N. meningitidis, but it lacks a polysaccharide capsule and the serosubtyping antigen PorA. Carriage studies have demonstrated that N...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.3.373

    authors: Gorringe AR

    更新日期:2005-06-01 00:00:00

  • What can be done to make vaccines more trendy?

    abstract::Incredibly, vaccines currently capture only about 2% of the world's pharmaceutical market, despite the fact that they can be credited with saving more lives and preventing more suffering and disability than any other form of medical activity, with the possible exception of the provision of clean water. ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.4.1.23

    authors: Andre FE

    更新日期:2005-02-01 00:00:00

  • Immunization: a global challenge for the 21st Century.

    abstract::The 9th Canadian Immunization Conference was held on 5-8 December 2010 in Quebec City, Canada. Over 1000 academic, public health and vaccine industry scientists, nurses, pharmacists, physicians and policy makers attended the conference, which was organized by the Public Health Agency of Canada-Centre for Immunization ...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/erv.11.34

    authors: Langley JM,Naus M

    更新日期:2011-04-01 00:00:00

  • Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review.

    abstract:BACKGROUND:Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. OBJECTIVE:To describe the vaccine efficacy, immunoge...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1150182

    authors: Bakker M,Bunge EM,Marano C,de Ridder M,De Moerlooze L

    更新日期:2016-07-01 00:00:00

  • Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.

    abstract::Recombinant adenoviruses have emerged as promising viral vectors for CD8(+) T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8(+) T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-leve...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.88

    authors: Bassett JD,Swift SL,Bramson JL

    更新日期:2011-09-01 00:00:00

  • Insect cell technology is a versatile and robust vaccine manufacturing platform.

    abstract::Baculovirus and insect cell culture technologies have mostly been limited to research laboratories for the transient expression of target proteins for drug development purposes. With the renaissance of the vaccine field and the regulatory acceptance of recombinant DNA technology, the baculovirus expression system has ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.24

    authors: Mena JA,Kamen AA

    更新日期:2011-07-01 00:00:00

  • Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection.

    abstract::Notifications of infant deaths, assumed to be related to the introduction of new pentavalent DTwP-Hib-HBV childhood vaccines, caused, during 2008-2010 in few Asian countries, temporary interruptions of the respective vaccination programs. The sudden appearance of fatal cases was due to increased awareness/publicity an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.2015.1059759

    authors: Herzog C

    更新日期:2015-01-01 00:00:00

  • Cancer vaccines as a therapeutic strategy.

    abstract::The concept of cancer vaccines is as a therapeutic strategy to immunize the body against cancer antigens that may not be presented by the cancer itself, due to the marked immunosuppressive effects of the disease, which has been demonstrated in many different tumors. ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.3.6.665

    authors: Dalgleish AG

    更新日期:2004-12-01 00:00:00

  • Clinical development of MVA-based therapeutic cancer vaccines.

    abstract::Tumor-associated antigens (TAAs) have been formulated into vaccines that, combined with adjuvants, cytokines or other strategies to boost the immune response, are now in clinical development. Both humoral and cellular immune responses to TAAs have been generated using these vaccines. This approach relies on the patien...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.7.889

    authors: Acres B,Bonnefoy JY

    更新日期:2008-09-01 00:00:00

  • Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges.

    abstract::An urgent need exists for vaccines to prevent infections caused by nontypeable Haemophilus influenzae and Moraxella catarrhalis. These bacteria cause otitis media in children, a clinical problem associated with enormous morbidity and cost. H. influenzae and M. catarrhalis also cause lower respiratory tract infections ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.6.843

    authors: Murphy TF

    更新日期:2005-12-01 00:00:00

  • Molecular mechanisms for enhanced DNA vaccine immunogenicity.

    abstract::In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this proble...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1124762

    authors: Li L,Petrovsky N

    更新日期:2016-01-01 00:00:00

  • Antigen-tailored therapy based on the inflammatory theory of atherosclerosis.

    abstract::In recent years, considerable data has been provided to support the role of the immune system in atherosclerosis. These reports came from studies involving knockout murine models of atherosclerosis and human subjects. The notion that inflammatory mechanisms are operable in atherogenesis has fueled a series of studies ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.5.605

    authors: Harats D,George J

    更新日期:2004-10-01 00:00:00

  • Vaccine development for syphilis.

    abstract:INTRODUCTION:Syphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-oriented syphilis prevent...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1203262

    authors: Lithgow KV,Cameron CE

    更新日期:2017-01-01 00:00:00

  • Improving vaccines by incorporating immunological coadjuvants.

    abstract::While vaccination continues to be the most successful interventionist health policy to date, infectious disease remains a significant cause of death worldwide. A primary reason that vaccination is not able to generate effective immunity is a lack of appropriate adjuvants capable of initiating the desired immune respon...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.4.559

    authors: Fraser CK,Diener KR,Brown MP,Hayball JD

    更新日期:2007-08-01 00:00:00

  • Do new TB vaccines have a place in the Expanded Program on Immunization?

    abstract::Several new TB vaccines are currently undergoing clinical trials. Among the most promising is a vaccine based upon the modified vaccinia virus Ankara-expressing mycobacterial antigen 85A (MVA85A). Given the widespread use of the current TB vaccine, BCG, many of the new TB vaccines are being tested for their ability to...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.11.144

    authors: McMurray DN

    更新日期:2011-12-01 00:00:00

  • Current challenges for cancer vaccine adjuvant development.

    abstract:INTRODUCTION:Although much progress has been made in the last decade(s) toward development of effective cancer vaccines, there are still important obstacles to therapeutic successes. New generations of cancer vaccines will benefit from a combination adjuvant approach that targets multiple branches of the immune respons...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2018.1434000

    authors: Bowen WS,Svrivastava AK,Batra L,Barsoumian H,Shirwan H

    更新日期:2018-03-01 00:00:00

  • Survey of vaccine distribution and delivery issues in the USA: from pediatrics to pandemics.

    abstract::Vaccine distribution and delivery has become an issue of significant interest, given the threat of a pandemic influenza outbreak and the resulting need for coordinated efforts to distribute and deliver pandemic influenza vaccines into the hands of healthcare workers responsible for administering them. This review prov...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.6.981

    authors: Jacobson SH,Sewell EC,Jokela JA

    更新日期:2007-12-01 00:00:00

  • Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

    abstract::Although mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.166

    authors: Doroud D,Rafati S

    更新日期:2012-01-01 00:00:00

  • Pediatric combined formulation DTaP-IPV/Hib vaccine.

    abstract::Combination vaccines have been used for many years in the USA as part of the primary infant immunization series. However, the current program still requires up to 24 injections by 18 months of age. The Advisory Committee on Immunization Practices in the USA recommends the use of combination vaccines whenever possible....

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.59

    authors: White C,Halperin SA,Scheifele DW

    更新日期:2009-07-01 00:00:00